Drug Trial Radar · NCT06224595
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic Profiles and Food Effect of CS32582 Capsules
Last checked: Nov 19, 2026Latest source record: Dec 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
112
Actual
Start
Mar 28, 2024
Primary completion
Nov 27, 2024
Study completion Nov 27, 2024
Sponsor
- Lead sponsor
- Chipscreen Biosciences, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 25, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CS32582 after single or multiple oral administration, as well as the food effect on the pharmacokinetics in healthy subjects.
Conditions
- Healthy
Interventions
CS32582 capsuleDrug
Participants receive CS32582 orally single or multiple doses
Placebo capsuleDrug
Participants receive placebo matching CS32582 orally single or multiple doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and Severity of Adverse Events (AEs)Time frame: From the time of signing the informed consent form to 7 days after the last administration of the drug
- Pharmacokinetic parameters - Area Under the Curve(AUC)Time frame: From time 0 to 48 hours for single dose. From time 0 to 48 hours after the last dose for multiple doses. From time 0 to 48 hours after each period's dosing for food effect study.
- Pharmacokinetic parameters - Peak Plasma Concentration (Cmax)Time frame: From time 0 to 48 hours for single dose. From time 0 to 48 hours after the last dose for multiple doses. From time 0 to 48 hours after each period's dosing for food effect study.
- Pharmacokinetic parameters - Time of Peak Concentration(Tmax)Time frame: From time 0 to 48 hours for single dose. From time 0 to 48 hours after the last dose for multiple doses. From time 0 to 48 hours after each period's dosing for food effect study.
- Pharmacokinetic parameters - Plasma Elimination Half-Life(t1/2)Time frame: From time 0 to 48 hours for single dose. From time 0 to 48 hours after the last dose for multiple doses. From time 0 to 48 hours after each period's dosing for food effect study.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.